Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
14.71 USD
-0.88%
Market Closed
Updated:
Apr 28, 2024
Y-mAbs Therapeutics Inc
Revenue
|
Y-mAbs Therapeutics Inc
Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Revenue
$84.8m
|
CAGR 3-Years
60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Y-mAbs Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
|
Total Revenue:
84.8m
USD
|
|
United States:
67.8m
USD
|
|
Non-Us:
16.5m
USD
|
Breakdown by Segments
Y-mAbs Therapeutics Inc
Y-mAbs Therapeutics Inc
|
Total Revenue:
84.8m
USD
|
|
Product:
84.3m
USD
|
|
License:
500k
USD
|
See Also
What is Y-mAbs Therapeutics Inc's Revenue?
Revenue
84.8m
USD
84.8m
USD
Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Revenue amounts to 84.8m USD.
What is Y-mAbs Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
60%
60%
Over the last year, the Revenue growth was 30%. The average annual Revenue growth rates for Y-mAbs Therapeutics Inc have been 60% over the past three years .
You don't have any saved screeners yet
